Date published: 2026-3-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

CD32-B_Fc γ RIIb Inhibitors

CD32-B/FcγRIIb inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of CD32-B, also known as Fc gamma receptor IIB (FcγRIIb), a low-affinity receptor for the Fc region of immunoglobulin G (IgG). CD32-B is unique among the Fcγ receptors because it possesses an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail, which confers inhibitory signaling capabilities. This receptor is primarily expressed on the surface of B cells, monocytes, macrophages, and dendritic cells, and it plays a crucial role in downregulating immune responses by dampening the activation of these cells. Upon binding to immune complexes (antigen-antibody complexes), CD32-B recruits phosphatases that dephosphorylate key signaling molecules, thereby inhibiting activation pathways that would otherwise lead to immune cell activation, proliferation, and cytokine production. By inhibiting CD32-B, researchers can disrupt these negative feedback mechanisms, allowing for the study of immune regulation and signaling.

In research settings, CD32-B/FcγRIIb inhibitors are valuable tools for exploring the complex regulatory networks that balance immune activation and suppression. By blocking CD32-B activity, scientists can investigate how the inhibition of this receptor affects the activation thresholds of B cells and other immune cells, thereby providing insights into the mechanisms that maintain immune homeostasis. This can lead to a better understanding of the role of CD32-B in modulating immune responses, particularly in contexts where overactivation or insufficient activation of immune cells can have significant consequences. Additionally, CD32-B inhibitors allow researchers to study the interactions between CD32-B and other Fcγ receptors, elucidating the balance between activating and inhibitory signals that control immune cell function. Through these studies, the use of CD32-B/FcγRIIb inhibitors contributes to a deeper understanding of immune regulation, the role of Fcγ receptors in immune complex handling, and the intricate signaling pathways that ensure appropriate immune responses to various stimuli.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$62.00
$85.00
$356.00
155
(1)

BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation, which can decrease the expression of FCGR2B due to NF-κB’s role in its transcriptional regulation.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor that prevents phosphorylation of AKT, potentially reducing FCGR2B-mediated signaling which can be PI3K/AKT pathway dependent.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is another PI3K inhibitor that can attenuate downstream signaling cascades such as AKT, potentially modulating the activity of FCGR2B.

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$63.00
$92.00
$250.00
$485.00
$1035.00
$2141.00
69
(5)

Cyclosporin A inhibits calcineurin, thereby affecting NFAT (nuclear factor of activated T-cells) which indirectly influences the expression of FCGR2B.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$155.00
$525.00
(1)

Monensin A is an ionophore that disrupts lysosomal pH, potentially affecting the recycling and expression of FCGR2B on the cell surface.

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$31.00
$53.00
$124.00
$374.00
25
(3)

Brefeldin A disrupts Golgi apparatus function, which can lead to mislocalization of FCGR2B, impairing its surface expression and function.

Stat3 inhibitor V, stattic

19983-44-9sc-202818
sc-202818A
sc-202818B
sc-202818C
sc-202818D
sc-202818E
sc-202818F
25 mg
100 mg
250 mg
500 mg
1 g
2.5 g
5 g
$130.00
$196.00
$274.00
$512.00
$731.00
$1408.00
$2091.00
114
(3)

Stattic selectively inhibits STAT3, which can downregulate the expression of FCGR2B by interfering with STAT3-mediated signaling pathways.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a Src family kinase inhibitor that may reduce FCGR2B signaling through its inhibition of Fc receptor-mediated phosphorylation pathways.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$94.00
$227.00
30
(1)

PP2 is an inhibitor of Src family kinases which are involved in FCGR2B signaling; inhibition could reduce FCGR2B-mediated immune responses.

SU6656

330161-87-0sc-203286
sc-203286A
1 mg
5 mg
$57.00
$133.00
27
(1)

SU6656 is another Src family kinase inhibitor, potentially decreasing FCGR2B-mediated activities by blocking Src-related pathways.